New study highlights the dual effects of new osteoporosis therapy on bone tissue in postmenopausal women.
Sclerostin is a protein produced by osteocytes in the bone that inhibits bone formation. A recent analysis of results from a clinical trial reveals the beneficial effects of romosozumab, an antibody therapy that targets sclerostin, on bone tissue in postmenopausal women with osteoporosis. The findings are published in the Journal of Bone and Mineral Research.
Romosozumab increases serum markers of bone formation and decreases those of bone breakdown, or resorption. This is associated with an increased bone mineral density and a reduced risk of bone fractures.
"Romosozumab is the first osteoporosis therapy with a dual effect on bone tissue, increasing bone formation and decreasing resorption" said lead author Dr. Pascale Chavassieux, of the University of Lyon, in France.